Sudo Biosciences is a biopharmaceutical company committed to designing and developing novel, best-in-class medicines to transform patients’ lives. Their lead programs target the tyrosine kinase 2 (TYK2) pseudokinase domain. TYK2 is a key mediator in cytokine signaling pathways that have been linked to a broad range of immune-mediated inflammatory conditions.


Biotechnology

Pharmaceutical

Sudo Biosciences

Scott Byrd

Imran B.

David Hennings

Anjali Pandey

Ian W. Mills

Gordon McMurray

The Leadership Team at Sudo Biosciences is responsible for setting the strategic direction of the company and overseeing the development of innovative biopharmaceutical therapies. Comprising executives with expertise in clinical operations, finance, manufacturing, and medical development, the team collaborates to ensure the successful advancement of TYK2-targeted programs, driving the company's mission to improve patient outcomes in immune-mediated inflammatory diseases.

Leadership Team

Operations Team

Leadership Team

About

Team members

Other teams at Sudo Biosciences

Operations Team